Soleno Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

Soleno Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: SLNO), announced that CEO Anish Bhatnagar will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 2:40 PM ET.

Rhea-AI Summary

Soleno Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: SLNO), announced that CEO Anish Bhatnagar will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 2:40 PM ET.

A live audio webcast and replay can be accessed on the company’s website. Soleno focuses on developing therapeutics for rare diseases, particularly DCCR extended-release tablets for treating Prader-Willi Syndrome, currently in a Phase 3 clinical program.

Argus Session date unavailable

+0.75% session move Open Argus

Details

News Market Reaction – SLNO

The recorded move for SLNO in the trading session of this news was +0.75%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 2:40 PM Eastern Time.

A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What event is Soleno Therapeutics participating in on September 30, 2021?

Soleno Therapeutics will participate in the 2021 Cantor Virtual Global Healthcare Conference.

Who is the CEO of Soleno Therapeutics?

The CEO of Soleno Therapeutics is Anish Bhatnagar.

What is the focus of Soleno Therapeutics?

Soleno Therapeutics focuses on developing therapeutics for rare diseases.

What is Soleno's lead candidate in clinical development?

Soleno's lead candidate is DCCR extended-release tablets for the treatment of Prader-Willi Syndrome.

Where can I access the webcast of Soleno's presentation?

The webcast can be accessed on Soleno Therapeutics' website in the Investors section.